General Information of Drug (ID: DMLGQJR)

Drug Name
RG6007 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMLGQJR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [2]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [3]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [4]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [5]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [6]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [7]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [8]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [9]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [10]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HLA class I histocompatibility antigen, A alpha chain (HLA-A) TTOMP5Y HLAA_HUMAN Not Available [1]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [1]

References

1 Clinical pipeline report, company report or official report of Roche
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
4 Clinical pipeline report, company report or official report of Genmab.
5 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
7 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
8 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
9 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
10 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
11 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.